Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer — Stella

Recruiting

Back to Esophageal Cancer trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

Chinese PLA General Hospital, Beijing, Beijing Municipality

Key details

Phase

Large-scale testing

Sponsor

Sunshine Lake Pharma Co., Ltd.

Enrollment target

~416 participants

Started

January 2021

Primary completion

August 2026

Age range

18 Years – 80 Years

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov